Replidyne at buy by Merrill

Merrill Lynch analyst David Munno rated Replidyne, Inc. at a buy on an expected Food and Drug Administration approvable letter on Oct. 20 for faropenem for the treatment of community acquired pneumonia and acute bacterial sinusitis, without the need for new studies. Approvable letters are also expected pending new studies for chronic bronchitis and skin infections. The analyst estimates Replidyne will be worth $14 or higher with the approvable letters and no new studies and $5 to $6 if new studies are required. Shares of the Louisville, Ky.-based biopharmaceutical company were up 62 cents, or 6.52%, at $10.13. (Nasdaq: RDYN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.